Opinion|Videos|February 17, 2025
Treating Atopic Dermatitis in a 35-Year-Old Man With Multiple Atopic Conditions
Author(s)Raj Chovatiya, MD, PhD, MSCI
The panelist discusses how a 35-year-old man with atopic dermatitis requires personalized, comprehensive management considering skin of color complexities, focusing on trigger identification, targeted therapies like dupilumab, and holistic approach to inflammation, skin barrier protection, and aesthetic concerns.
Advertisement
Episodes in this series
Video content above is provided by the following:
- Please provide your initial impressions of this case. What are key aspects of this case to consider in your plan for management?
- What is unique about diagnosing and managing atopic dermatitis in skin of color, and how does it change your treatment approach, if at all?
- Describe your approach to treatment options for this patient. What is your assessment of this patient’s disease severity?
- What are some of the potential benefits of dupilumab treatment for this patient?
- How would you address this patient’s concern for his postinflammatory hyperpigmentation?
- What practical advice can you provide to this patient to better help him identify and manage personal triggers?
Advertisement
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
2
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
5